Jefferies Upgrades Ionis Pharmaceuticals to Buy, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Akash Tewari has upgraded Ionis Pharmaceuticals (NASDAQ:IONS) from Underperform to Buy and raised the price target from $29 to $75.
July 16, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies analyst Akash Tewari has upgraded Ionis Pharmaceuticals from Underperform to Buy and significantly raised the price target from $29 to $75.
The upgrade from Underperform to Buy and the substantial increase in the price target from $29 to $75 by a reputable analyst at Jefferies is likely to positively impact the stock price of Ionis Pharmaceuticals in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100